Scientists discover new candidate gene for Dravet syndrome

Dravet syndrome is a severe genetic epilepsy that appears early in life. About 75 percent of cases can be attributed to mutations in the SCN1A gene encoding the sodium channel NaV1.1. The remaining patients with this syndrome are without a definitive molecular genetic diagnosis. Research presented today at the American Epilepsy Society's 65th Annual Meeting has found a non-SCN1A candidate gene and suggests that Dravet syndrome may be caused by any one of a number of yet unidentified genes.

In order to identify novel candidate genes for Dravet syndrome, investigators from the University of Washington selectively sequenced the protein coding regions of all genes from six non-SCN1A patients. (Platform C.03) Their analysis revealed an unexpected, and previously unidentified de novo SCN1A mutation in one of the patients. Another patient was discovered to carry a de novo, rare mutation in a GABA-receptor gene, GABRA1.

"The GABRA1 gene is an excellent new candidate gene for Dravet syndrome and deserves follow-up in a larger series of patients," says Heather Mefford, the lead author. "The fact that we did not find mutations in the same genes in the remaining four patients suggests that there are several more genes for Dravet syndrome yet to be discovered."

Dr. Mefford noted further that the sequencing approach used in the analysis, called whole exome sequencing, is an effective approach in identifying candidate Dravet genes. Whole exome sequencing looks at the protein coding region in the whole human gene pool for mutations that may cause disease.

The investigators will be assessing additional patients for other potential candidate genes for Dravet syndrome.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Gene variant in Andean populations could help predict blood cancer treatment outcomes